Covance's Asia Focus Sees Expansion in Singapore Services

By Dan Stanton

- Last updated on GMT

Related tags Clinical research Clinical trial

Covance expands Singapore site
Covance expands Singapore site
Covance says anticipated future demand across the Asia Pacific region drove the latest expansion of its services in Singapore.

The company, which ‘cut the ribbon’ on the 29,000sq ft laboratory expansion this morning, is effectively doubling its genomics offering, as well as adding anatomic pathology and nutritional chemistry capabilities at its site in Singapore, citing current and future growth of drug development in the Asia Pacific region.

“For the last 13 years Covance has provided central laboratory testing services in Singapore, where we have seen increasing demand for efficient, high-quality clinical trial data and support,”​ said Jon Koch - Corporate Vice President and Global General Manager, Central Laboratory Services, Covance – in a press statement.

Koch added that on top of continued commitment in the region, the expansion helps to serve “local and multinational customers' R&D needs in key therapeutic areas like oncology and metabolic diseases.”

According to the company, this latest investment in Singapore makes Covance’s facility the largest of its kind on the island state and is part of an overall Asia-Pacific strategy which includes recent developments in Japan and China.

Last December Covance received GLP certification​ from China’s Food and Drug Administration (CFDA​ – previously known as the SFDA) at its Shanghai early-phase facility, boosting its preclinical service offering in the country, and – according to a statement to Outsourcing-Pharma.com at the time - becoming “the only global CRO with SFDA GLP certification.”

Covance also has a grip in the Japanese preclinical market with two sites in Japan, plus collaborations with local firms​.


The island state has, due to its location and national incentives, become a hive of pharma activity and a gateway into the rest of Asia.

Regarding this latest investment, Lai, Director, Biomedical Sciences Group, from the Economic Development Board of Singapore (EDB), told Outsourcing-Pharma.com:“Covance’s expansion in Singapore demonstrates our attractiveness as a strategic location for CROs to tap on the fast growing drug development and clinical research opportunities in the region."

Singapore has drawn much interest from global manufacturing firms, with Amgen’s recent $200m​ spend on a new biomanufacturing facility following the lead of Novartis and its $500m investment​ last November.

Lai continued to say: "We are pleased that these companies have leveraged Singapore as a base for them to assess and access new growth markets in Asia. These investments continue to help us build up the translational and clinical research infrastructure in Singapore, and augments the integrated biomedical sciences ecosystem that we have built up over the years."

However, companies have had a mixed reaction to clinical research in Singapore in recent months. Whilst PPD expanded​ its lab services there in February, Pfizer announced it would shutter its clinical research unit​ on the island by the end of the year.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us